Melissa M. Hardesty, MD, discusses OS and subgroup data from the OVARIO study of niraparib and bevacizumab maintenance in newly diagnosed ovarian cancer.
Melissa Hardesty, MD
Advertisement
Articles by Melissa Hardesty, MD
Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses the safety and efficacy of the bevacizumab/PARP inhibitor combination in ovarian cancer.
Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses second-line maintenance therapy after frontline chemotherapy for patients with ovarian cancer.
Advertisement
Latest Updated Articles
Dr Hardesty on Updated Data With Frontline Niraparib Plus Bevacizumab Maintenance in Advanced Ovarian CancerPublished: March 31st 2025 | Updated:
Dr. Hardesty on Second-Line Maintenance Therapy for Ovarian CancerPublished: July 17th 2018 | Updated:
Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian CancerPublished: August 17th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5